University of Chicago Extends Collaboration with AbbVie to Advance Clinical Research and Patient Outcomes in Oncology
“Our partnership with the University of Chicago is driven by our shared dedication to advancing cancer research and clinical innovation,” said Andrew Souers, PhD, vice president, oncology discovery research at AbbVie. “While we have made significant progress in cancer research, there is more to accomplish together. We look forward to deepening our long-standing collaboration to continue delivering meaningful, lasting impact for people living with cancer.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.